We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+4.86%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$8.07B
AUM Growth
+$160M
(+2%)
Cap. Flow
-$9.82B
Cap. Flow
% of AUM
-121.72%
Top 10 Holdings %
Top 10 Hldgs %
33.87%
Holding
157
New
25
Increased
29
Reduced
33
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$192M |
| 2 |
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
|
+$173M |
| 3 |
Merck
MRK
|
+$94.1M |
| 4 |
Tenet Healthcare
THC
|
+$83.4M |
| 5 |
DaVita
DVA
|
+$79.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$9.91B |
| 2 |
Eli Lilly
LLY
|
+$193M |
| 3 |
Amgen
AMGN
|
+$156M |
| 4 |
Cigna
CI
|
+$151M |
| 5 |
Elevance Health
ELV
|
+$148M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98% |
| 2 | Miscellaneous | 1.49% |
| 3 | Financials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
HCA Healthcare
HCA
$92.4B
| $46.8M | 0.58% |
+482,400
| New | +$46.8M |
|
52
Adicet Bio
ACET
$89.1M
| $46.3M | 0.57% |
+43,128
| New | +$79.1M |
|
53
Ironwood Pharmaceuticals
IRWD
$674M
| $45.2M | 0.56% |
3,497,525
-1,905,564
| -35% | -$23.7M |
|
54
X4 Pharmaceuticals
XFOR
$347M
| $42.8M | 0.53% |
10,383
| – | – |
|
|
LPNT
55
DELISTED
LifePoint Health, Inc.
LPNT
| $42.4M | 0.53% |
+902,825
| New | +$43.4M |
|
|
SCPH
56
DELISTED
scPharmaceuticals
SCPH
| $42.3M | 0.52% |
3,409,865
| – | – |
|
57
Intuitive Surgical
ISRG
$134B
| $42.1M | 0.52% |
306,000
-154,800
| -34% | -$21.6M |
|
58
argenx
ARGX
$61.6B
| $40.2M | 0.5% |
500,000
| – | – |
|
59
Stryker
SYK
$108B
| $38M | 0.47% |
236,300
-49,700
| -17% | -$8.01M |
|
|
PVLA
60
Palvella Therapeutics
PVLA
$2.16B
| $37.9M | 0.47% |
69,375
-21,370
| -24% | -$13.2M |
|
61
Assembly Biosciences
ASMB
$590M
| $35.4M | 0.44% |
60,097
-39,739
| -40% | -$24.6M |
|
|
OBSV
62
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $35.2M | 0.44% |
2,605,531
| – | – |
|
63
Pfizer
PFE
$158B
| $34.9M | 0.43% |
1,035,028
| – | – |
|
|
EVHC
64
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $33.6M | 0.42% |
875,400
| – | – |
|
|
65
Cigna
CI
$74.2B
| $32.3M | 0.4% |
192,300
-777,000
| -80% | -$151M |
|
66
Heron Therapeutics
HRTX
$59.9M
| $31.5M | 0.39% |
1,139,800
+489,800
| +75% | +$11.1M |
|
|
DCPH
67
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $30.7M | 0.38% |
1,532,900
+356,830
| +30% | +$9.04M |
|
68
Teleflex
TFX
$5.55B
| $29.8M | 0.37% |
+117,000
| New | +$30.7M |
|
69
Gilead Sciences
GILD
$182B
| $27.5M | 0.34% |
364,600
-157,000
| -30% | -$12.5M |
|
|
RDUS
70
DELISTED
Radius Health, Inc.
RDUS
| $27.4M | 0.34% |
762,900
-608,800
| -44% | -$22M |
|
|
ALPN
71
DELISTED
Alpine Immune Sciences Inc
ALPN
| $26.4M | 0.33% |
3,298,516
| – | – |
|
72
eHealth
EHTH
$29.6M
| $26.3M | 0.33% |
1,834,700
| – | – |
|
|
VRNA
73
DELISTED
Verona Pharma
VRNA
| $25M | 0.31% |
1,250,396
| – | – |
|
|
SVA
74
DELISTED
Sinovac Biotech, Ltd
SVA
| $24.4M | 0.3% |
2,839,500
| – | – |
|
75
Sarepta Therapeutics
SRPT
$2.16B
| $23.8M | 0.3% |
321,600
+222,200
| +224% | +$14.8M |
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q1 2018 Portfolio in Review
As of Q1 2018, OrbiMed held 157 positions worth $8.07B, up 2% from $7.91B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
OrbiMed withdrew a net $9.82B in Q1 2018, closing 16 positions and reducing 33 holdings. Its most notable exit was Eli Lilly, an estimated $193M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, OrbiMed opened a new position in ARMO BioSciences, Inc. Common Stock worth $154M.
- OrbiMed's largest Q1 2018 buy was ARMO BioSciences, Inc. Common Stock: 4,118,903 shares worth $154M.
- OrbiMed added most to Bristol-Myers Squibb in Q1 2018, an estimated $192M increase.
- OrbiMed's biggest Q1 2018 reduction was Loxo Oncology, Inc, cutting an estimated $9.91B.
- OrbiMed fully exited Eli Lilly in Q1 2018, selling an estimated $193M.
- OrbiMed's ten largest holdings make up 34% of its $8.07B portfolio in Q1 2018.
- OrbiMed opened 25 new positions and closed 16 in Q1 2018.
- OrbiMed's portfolio value rose 2% quarter-over-quarter to $8.07B.
Based on OrbiMed's 13F filing for Q1 2018, filed 15 May 2018.